By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tolerx, Inc. 

300 Technology Square
3rd Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-354-8100 Fax: 617-354-8300

Tolerx, Inc. is a biopharmaceutical company engaged in discovering and developing new therapies designed to treat patients with immune related diseases - such as type 1 diabetes, psoriasis, and others - by reprogramming the immune system following a short course of therapy. Tolerx is developing its CD3 monoclonal antibody, otelixizumab, in collaboration with GlaxoSmithKline and the Juvenile Diabetes Research Foundation. Tolerx is developing with Genentech, a CD4 monoclonal antibody, MTRX1011. Tolerx is also engaged in the preclinical development of other antibodies that may shift or modulate the immune system.

For more information about Tolerx, please visit the company’s website at

Key Statistics

Ownership: Private

Web Site: Tolerx, Inc.

Company News
Tolerx, Inc. Cuts Staff, Auctioning Assets After Phase 3 Failure 10/7/2011 9:31:26 AM
Tolerx, Inc. Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses 4/5/2011 7:18:12 AM
Tolerx, Inc. and GlaxoSmithKline (GSK) Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 3/11/2011 7:13:01 AM
Tolerx, Inc. Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody 2/9/2011 7:55:27 AM
Tolerx, Inc. Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 12/14/2010 7:21:11 AM
Tolerx, Inc. and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518, a First-in-Class Anti-GITR Antibody for Cancer Treatment 12/1/2010 7:29:16 AM
Tolerx, Inc. Forms Scientific Advisory Board to Advance Research in Type 1 Diabetes 11/2/2010 11:24:02 AM
Tolerx, Inc. Presents Research at European Diabetes Meeting and Enrolls First Patient in Europe in the DEFEND-2 Phase 3 Clinical Study in Type 1 Diabetes 9/23/2010 8:33:27 AM
Tolerx, Inc. Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 8/4/2010 9:16:59 AM
Tolerx, Inc. Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 6/28/2010 9:12:55 AM